ダウンロード数: 1076
このアイテムのファイル:
| ファイル | 記述 | サイズ | フォーマット | |
|---|---|---|---|---|
| 33_1728.pdf | 262.28 kB | Adobe PDF | 見る/開く |
| タイトル: | 膀胱癌, 腎細胞癌に対するUFTの使用経験 |
| その他のタイトル: | Clinical experience of tegafur-uracil (UFT) against bladder cancer and renal cell carcinoma |
| 著者: | 中神, 義三  林, 昭棟 伊藤, 博 平沢, 精一 淡輪, 邦男 藤岡, 良彰 小川, 秀弥 田中, 求平 山田, 記道 石井, 洋二 引間, 規夫 |
| 著者名の別形: | Nakagami, Yoshizo Lin, Tsaw Tung Ito, Hiroshi Hirasawa, Seiichi Tannawa, Kunio Fujioka, Yoshiaki Ogawa, Hideya Tanaka, Kyuhei Yamada, Norimichi Ishii, Yoji Hikima, Norio |
| キーワード: | Adult Aged Antineoplastic Combined Chemotherapy Protocols/therapeutic use Carcinoma, Renal Cell/drug therapy Carcinoma, Transitional Cell/drug therapy Female Humans Kidney Neoplasms/drug therapy Male Middle Aged Tegafur/administration & dosage Uracil/administration & dosage Urinary Bladder Neoplasms/drug therapy |
| 発行日: | Oct-1987 |
| 出版者: | 泌尿器科紀要刊行会 |
| 誌名: | 泌尿器科紀要 |
| 巻: | 33 |
| 号: | 10 |
| 開始ページ: | 1728 |
| 終了ページ: | 1732 |
| 抄録: | The safety of prolonged administration of UFT in which tegafur and uracil were mixed in a ratio of 1:4 in molar fraction was studied in 44 cases of bladder cancer and 10 cases of renal cell carcinoma. Daily doses of UFT were 300-600 mg, and average total doses administered were 102.0 g for bladder cancer and 116.6 g for renal cell carcinoma cases. Incidence of adverse effects were 25.0% in bladder cancer and 18.5% in renal cell carcinoma cases. Anorexia, nausea, vomiting and decrease in WBC were observed, but rates of having discontinued the administration of UFT were very low, being 9.1% in bladder cancer and 10.0% in renal cell carcinoma. Thus, UFT was considered to be tolerable during prolonged use in bladder cancer and renal cell carcinoma and also a drug in which more usefulness is expected in multidisciplinary treatments in future. |
| URI: | http://hdl.handle.net/2433/119290 |
| PubMed ID: | 3128071 |
| 出現コレクション: | Vol.33 No.10 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。